Literature DB >> 2657099

Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity.

C Peng1, B K Ho, T W Chang, N T Chang.   

Abstract

It is generally believed that the gag gene product of human immunodeficiency virus type 1 (HIV-1) is processed into several core proteins by a virus-specific protease. We used deletion mutation analysis to study the role of HIV-specific protease in the processing of core proteins and its requirement for viral infectivity. Several mutant genomes with deletions in the protease gene were constructed. A mammalian cell line, COS-M6, transfected with the wild-type viral genome was shown to produce virions containing processed core proteins, while COS-M6 cells transfected with two mutated genomes could express only the core protein precursor, Pr56gag. The wild-type transfectant produced infectious virus; both transfectants expressing the mutated genomes also produced virions, and one of them still retained reverse transcriptase activity. However, the mutant viral particles were devoid of infectivity. Virions with a distinct central core and an electron-dense nucleoid budded out from the plasma membrane of COS-M6 cells transfected with the wild-type genome. In contrast, noninfectious virions that budded either into cytoplasmic vacuoles or out from the plasma membrane of COS-M6 cells transfected with mutant genomes contained ring-shaped nucleoids. These results indicate that the HIV-1 protease plays a role not only in the maturation of the core proteins but also in the assembly of the virus and thus is required for viral infectivity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2657099      PMCID: PMC250724     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

2.  Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2).

Authors:  R Sanchez-Pescador; M D Power; P J Barr; K S Steimer; M M Stempien; S L Brown-Shimer; W W Gee; A Renard; A Randolph; J A Levy
Journal:  Science       Date:  1985-02-01       Impact factor: 47.728

3.  Nucleotide sequence of the AIDS virus, LAV.

Authors:  S Wain-Hobson; P Sonigo; O Danos; S Cole; M Alizon
Journal:  Cell       Date:  1985-01       Impact factor: 41.582

4.  Immunoassay for the detection and quantitation of infectious human retrovirus, lymphadenopathy-associated virus (LAV).

Authors:  J S McDougal; S P Cort; M S Kennedy; C D Cabridilla; P M Feorino; D P Francis; D Hicks; V S Kalyanaraman; L S Martin
Journal:  J Immunol Methods       Date:  1985-01-21       Impact factor: 2.303

5.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

6.  Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes.

Authors:  D Klatzmann; F Barré-Sinoussi; M T Nugeyre; C Danquet; E Vilmer; C Griscelli; F Brun-Veziret; C Rouzioux; J C Gluckman; J C Chermann
Journal:  Science       Date:  1984-07-06       Impact factor: 47.728

7.  Lymphadenopathy associated virus infection of a blood donor--recipient pair with acquired immunodeficiency syndrome.

Authors:  P M Feorino; V S Kalyanaraman; H W Haverkos; C D Cabradilla; D T Warfield; H W Jaffe; A K Harrison; M S Gottlieb; D Goldfinger; J C Chermann
Journal:  Science       Date:  1984-07-06       Impact factor: 47.728

8.  High level transient expression of a chloramphenicol acetyl transferase gene by DEAE-dextran mediated DNA transfection coupled with a dimethyl sulfoxide or glycerol shock treatment.

Authors:  M A Lopata; D W Cleveland; B Sollner-Webb
Journal:  Nucleic Acids Res       Date:  1984-07-25       Impact factor: 16.971

9.  Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome.

Authors:  G M Shaw; B H Hahn; S K Arya; J E Groopman; R C Gallo; F Wong-Staal
Journal:  Science       Date:  1984-12-07       Impact factor: 47.728

10.  Active site mutagenesis of the AIDS virus protease and its alleviation by trans complementation.

Authors:  S F Le Grice; J Mills; J Mous
Journal:  EMBO J       Date:  1988-08       Impact factor: 11.598

View more
  116 in total

1.  Genetic selection for dissociative inhibitors of designated protein-protein interactions.

Authors:  S H Park; R T Raines
Journal:  Nat Biotechnol       Date:  2000-08       Impact factor: 54.908

2.  Segmental analysis of molecular surface electrostatic potentials: application to enzyme inhibition.

Authors:  Tore Brinck; Ping Jin; Yuguang Ma; Jane S Murray; Peter Politzer
Journal:  J Mol Model       Date:  2003-02-21       Impact factor: 1.810

3.  Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release.

Authors:  H G Göttlinger; T Dorfman; J G Sodroski; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

4.  Validating the vitality strategy for fighting drug resistance.

Authors:  Nidhi Singh; Maria P Frushicheva; Arieh Warshel
Journal:  Proteins       Date:  2012-01-31

5.  Phosphorylation and proteolytic cleavage of gag proteins in budded simian immunodeficiency virus.

Authors:  Sarah M Rue; Jason W Roos; Patrick M Tarwater; Janice E Clements; Sheila A Barber
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

6.  p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease.

Authors:  M Huang; J M Orenstein; M A Martin; E O Freed
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

7.  Active foamy virus proteinase is essential for virus infectivity but not for formation of a Pol polyprotein.

Authors:  J Konvalinka; M Löchelt; H Zentgraf; R M Flügel; H G Kräusslich
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

8.  Retroviral properties inherent to viral erythrocytic infection in sea bass.

Authors:  R M Pintó; E Ribes; J Jofre; A Bosch
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

9.  Analysis and characterization of dimerization inhibition of a multi-drug-resistant human immunodeficiency virus type 1 protease using a novel size-exclusion chromatographic approach.

Authors:  David A Davis; Irene R Tebbs; Sarah I Daniels; Stephen J Stahl; Joshua D Kaufman; Paul Wingfield; Michael J Bowman; Jean Chmielewski; Robert Yarchoan
Journal:  Biochem J       Date:  2009-04-15       Impact factor: 3.857

10.  Enzymatic and structural analysis of the I47A mutation contributing to the reduced susceptibility to HIV protease inhibitor lopinavir.

Authors:  Klára Grantz Sasková; Milan Kozísek; Martin Lepsík; Jirí Brynda; Pavlína Rezácová; Jana Václavíková; Ron M Kagan; Ladislav Machala; Jan Konvalinka
Journal:  Protein Sci       Date:  2008-06-17       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.